$XBI $173.99 +4% 📈
COVID:
$EIGR +12% Phase 2 covid data published in Lancet Respiratory Medicine journal. source
PIPELINE:
SRNE +18% Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic. source
$RGNX +5% Presented positive interim data for RGX-121 at WorldSymposium. source
$SUPN +5% resubmits NDA for SPN-812 for ADHD in pediatric patients. source
$SAVA +35% updates regarding end of phase 2 meeting and 2021 milestones. source
$LCTX +12% Entered into licensing agreement with med device company; will collab on clinical trials and use their PDI platform. source
$CUE +9% Initiated phase 1 combo w/ Keytruda as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer. source
$QURE +8% Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease. source
$ERYP -15% TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis per IDMC. Final results expected Q4 2021. source
$AVRO +13% 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial. source
FINANCIAL:
$ETON +2% Sale of Neurology Portfolio. source